Percheron Therapeutics LimitedASX: PER

PER: Percheron and Invion Explore Cancer Combination Therapy

· Issued by Percheron Therapeutics Limited via ASX

Filed with ASX ·

ASX Announcement PERCHERON AND INVION TO EXPLORE NOVEL COMBINATION OF VISTA IMMUNOTHERAPY AND PHOTOSOFT™ FOR CANCER • Percheron Therapeutics and Invion to undertake preclinical studies evaluating HMBD-002, a VISTA targeting immune checkpoint inhibitor (ICI), in combination with Invion’s...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

Later from Percheron Therapeutics

All Percheron Therapeutics news releases